Yingjian He

Yingjian He

Auto-generated profile, based on publicly available information

Yingjian He

Breast Center, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2010 in BMC Public Health
Verified
Journal Article
Open access
PDF file
YXYin Yin Xia
Yin Yin Xia
DHDai Yu Hu
Dai Yu Hu
FLFei Ying Liu
Fei Ying Liu
XWXiaomeng Wang
Xiaomeng Wang
YYYan Li Yuan
Yan Li Yuan
SZSiyan Zhan
Siyan Zhan
Background: More than 1 million tuberculosis (TB) patients are receiving the standard anti-TB treatment provided by China National Tuberculosis Prevention and Control Scheme (CNTS) in China every year. Adverse reactions (ADRs) induced by anti-TB drugs could both do harm to patients and lead to anti-TB treatment failure. The ADACS aimed to explore ADRs' incidences, prognoses, economical and public health impacts for TB patients and TB control, and build a DNA bank of TB patients. Methods/Design: Multiple study designs were adopted. Firstly, a prospective cohort with 4488 sputum smears positive pulmonary tuberculosis patients was established. Patients were followed up for 6-9 months in 52 counties of four regions. Those suspected ADRs should be checked and confirmed by Chinese State Food and Drug Administration (SFDA). Secondly, if the suspected ADR was anti-TB drug induced liver injury (ATLI), a nested case-control study would be performed which comprised choosing a matched control and doing a plus questionnaire inquiry. Thirdly, health economical data of ADRs would be collected to analyze financial burdens brought by ADRs and cost-effectiveness of ADRs' treatments. Fourthly, a drop of intravenous blood for each patient was taken and saved in FTA card for DNA banking and genotyping. Finally, the demographic, clinical, environmental, administrative and genetic data would be merged for the comprehensive analysis. Discussion: ADACS will give an overview of anti-TB drugs induced ADRs' incidences, risk factors, treatments, prognoses, and clinical, economical and public health impacts for TB patients applying CNTS regimen in China, and provide suggestions for individualized health care and TB control policy.

18 June 2010
Verified
Journal Article
Closed access
ZYZu-Yao Yang
Zu-Yao Yang
SZSiyan Zhan
Siyan Zhan
BWBo Wang
Bo Wang
XYXin Yu
Xin Yu
ZSZheng Shu
Zheng Shu
HYHui-Ying Yang
Hui-Ying Yang

1 January 2025 in Translational Breast Cancer Research
Verified
Journal Article
Open access
PDF file
YHYingjian He
Yingjian He
Understanding the NATALEE trial—from a methodologist stand of point

5 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
JZJingyi Zhao
Jingyi Zhao
XKXinyu Kong
Xinyu Kong
TLTianye Lin
Tianye Lin
LHLi Hu
Li Hu
YHYingjian He
Yingjian He
YYYang Yang
Yang Yang
Background: This study aimed to quantify the frequency and imaging features of new CT-detected pulmonary abnormalities during breast cancer chemotherapy and examine their associations with cumulative cyclophosphamide and paclitaxel exposure. Methods: This single-center retrospective study included 223 patients who underwent an on-treatment chest CT under an early-pandemic infection-control policy. New CT-detected pulmonary abnormalities were defined as new findings on this on-treatment CT that were absent on the pretreatment staging CT. Cumulative cyclophosphamide (C) and paclitaxel (T) doses (mg/m2) were calculated from treatment cycles before the on-treatment CT and dichotomized at 1800 and 960 mg/m2, respectively. Associations were assessed using Firth-penalized logistic regression. Results: New CT-detected pulmonary abnormalities were identified in 34/223 patients (15.2%). Among 25 CT-positive cases with sufficiently detailed CT reports, patchy opacities (14/25, 56.0%) and ground-glass opacities (11/25, 44.0%) were the most frequent findings. Compared with patients with low cyclophosphamide and paclitaxel-equivalent exposure, combined exposure categories showed higher odds of the CT-detected outcome. In the Firth model, cyclophosphamide > 1800 mg/m2 was associated with the CT-detected outcome (adjusted odds ratio (OR) 2.38, 95% CI 1.06–5.71; p = 0.036), whereas paclitaxel-equivalent exposure > 960 mg/m2 (OR 2.46, 95% CI 0.86–6.80; p = 0.092) and age ≥ 60 years (OR 2.08, 95% CI 0.91–4.62; p = 0.083) were not statistically significant. Conclusions: New CT-detected pulmonary abnormalities were common during breast cancer chemotherapy (15.2%). Higher cumulative cyclophosphamide exposure was associated with the CT-detected outcome in multivariable analysis. Prospective longitudinal studies are needed to clarify the clinical significance of these abnormalities and their causality.